title: Hepatotoxicity in patients prescribed efavirenz or nevirapine.
abstract: OBJECTIVE
  For several years Nonnucleoside reverse transciptase inhibitors (NNRTIs) in antiretroviral therapy have been associated with hepatic side effects. Particularly the hepatotoxic potential of Nevirapine is well analysed today. We performed a prospective, multicenter study to compare the hepatotoxicity of Efavirenz (EFV) with that of Nevirapine (NVP) and to investigate further risk factors.
  
  
  METHODS
  The study included HIV-1-infected patients from five clinics and private medical practices in southwestern Germany who initiated an antiretroviral therapy with NVP or EFV between July 1998 and December 2001. Among 296 patients in total, 151 received EFV and 145 received NVP. Laboratory tests during the course of treatment included liver enzymes, HIV-RNA and CD4 cell-count. Additionally, signs of clinical hepatitis were recorded. Hepatotoxicity was graded in the manner of Sulkowsky et al. (2000), who used a scale modified from that of the AIDS Clinical Trials Group.
  
  
  RESULTS
  Hepatitis C virus and hepatitis B virus were detected in 10.1% and 4.1% of patients, respectively. The overall rate of severe hepatotoxicity (grade 3 to 4 elevations in aspartate aminotransferase and/or alanine aminotransferase) was 2 of 151 (1.3%) in patients prescribed EFV and 3 of 145 (2.1%) in patients prescribed NVP. Mild-to-moderate hepatotoxicity (grade 2 elevation) was observed in 6.0% (EFV) and 3.4% (NVP) of patients. Incidence of mild-to-moderate and severe hepatotoxicity did not differ significantly between the study groups. 3 of 14 patients (2.1%) with grade 2 elevation of liver enzymes (LEE) and 4 of 5 patients (80%) with grade 3 to 4 LEE were symptomatic. Only risk factor for the development of mild-to-moderate hepatotoxicity was hepatitis C coinfection.
  
  
  CONCLUSIONS
  Increases of liver enzymes during therapy with NVP or EFV are not unusual, but are mostly mild-to-moderate and asymptomatic. LEE occurs just as frequent in patients prescribed EFV as in patients prescribed NVP.
authors.affiliation: Department of Dermatology, University of Heidelberg, Germany. sandrabrueck@gmx.de
authors.forename: Sandra
authors.initials: S
authors.lastname: Brück
authors.forename: S
authors.initials: S
authors.lastname: Witte
authors.forename: J
authors.initials: J
authors.lastname: Brust
authors.forename: D
authors.initials: D
authors.lastname: Schuster
authors.forename: F
authors.initials: F
authors.lastname: Mosthaf
authors.forename: M
authors.initials: M
authors.lastname: Procaccianti
authors.forename: J A
authors.initials: JA
authors.lastname: Rump
authors.forename: H
authors.initials: H
authors.lastname: Klinker
authors.forename: D
authors.initials: D
authors.lastname: Petzold
authors.forename: M
authors.initials: M
authors.lastname: Hartmann
mesh_terms: D000328:Adult; D000480:Alkynes; D048588:Benzoxazines / Q000009:adverse effects*; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D016174:Hepacivirus / Q000378:metabolism; D006515:Hepatitis B virus / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; C098320:efavirenz